These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33164329)

  • 1. Advances and challenges of neoadjuvant therapy in pancreatic cancer.
    Yu Y; Zheng P; Chen Y; Wang B; Paul ME; Tao P; Wang D; Li H; Gu B; Gao L; Wang D; Chen H
    Asia Pac J Clin Oncol; 2021 Dec; 17(6):425-434. PubMed ID: 33164329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
    Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
    BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy].
    Zhang TP; Liu YZ; Cao Z
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):481-485. PubMed ID: 32610414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indications and efficacy of neoadjuvant therapy for pancreatic cancer].
    Gou SM; Wu HS
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(10):716-721. PubMed ID: 33721950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Ferrone CR; Marchegiani G; Hong TS; Ryan DP; Deshpande V; McDonnell EI; Sabbatino F; Santos DD; Allen JN; Blaszkowsky LS; Clark JW; Faris JE; Goyal L; Kwak EL; Murphy JE; Ting DT; Wo JY; Zhu AX; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    Ann Surg; 2015 Jan; 261(1):12-7. PubMed ID: 25599322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
    Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
    BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V
    Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress in neoadjuvant and transformation therapy of pancreatic cancer].
    Hu DD; Dai MH
    Zhonghua Wai Ke Za Zhi; 2017 Jan; 55(1):69-72. PubMed ID: 28056259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current consensus and controversy in neoadjuvant therapy for pancreatic cancer].
    Ou ZL; Li YX; Ji LD; Ke MJ
    Zhonghua Wai Ke Za Zhi; 2020 Feb; 58(2):99-104. PubMed ID: 32074807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adjuvant Chemotherapy after Surgery for Pancreatic Cancer].
    Furuse J
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):160-4. PubMed ID: 27067680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of neoadjuvant therapy in pancreatic cancer: a review.
    Russo S; Ammori J; Eads J; Dorth J
    Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Challenges and stratigies of neoadjuvant therapy for pancreatic cancer].
    Zhang TP; Luo WH; Qiu JD
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(10):704-707. PubMed ID: 33721947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant strategies for pancreatic cancer.
    Polistina F; Di Natale G; Bonciarelli G; Ambrosino G; Frego M
    World J Gastroenterol; 2014 Jul; 20(28):9374-83. PubMed ID: 25071332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Current and Future Status of Perioperative Therapy in Pancreatic Cancer].
    Ueno M
    Gan To Kagaku Ryoho; 2020 Apr; 47(4):578-581. PubMed ID: 32389955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.